Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will The Biosimilars Industry Peak By 2020?

This article was originally published in PharmAsia News

Executive Summary

Despite market-creation effects in EMs, government-backed ventures and non-traditional companies like Korea’s Samsung could fuel a hyper commoditized biosimilars market that leads to a turning point around 2020, Nomura says.

You may also be interested in...



Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News

Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.

With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim

MUMBAI - Keeping with its track record of launching a range of biosimilars before its peers, India's Dr. Reddy's Laboratories Ltd. is set to launch its indigenously developed pegylated filgrastim - a version of Amgen Inc.'s blockbuster Neulasta used to boost white blood cells in patients undergoing chemotherapy. Neulasta had global sales of around $3.6 billion last year, said an expert in the biotechnology industry

Topics

Related Companies

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel